This means that, while patients are still infected, they are at reduced risk of developing complications such as fibrosis, which can eventually result in cirrhosis and liver cancer.
According to Prensa Latina, even five years after vaccination, 80% of people kept their viral load under control and 50% had an undetectable viral load.
Patients in South Korea, New Zealand, Singapore, Australia, the Philippines, Chinese Taipei, Thailand and Hong Kong reported positive outcomes following the treatment, which was recognized by their respective regulatory agencies.
HeberNasvac, in partnership with French company Abivax, was recognized for its effectiveness in treating hepatitis B at the annual meeting of the American Society of Liver Diseases.
The regimen of this immunogen in Cuba is nasal administration combined with subcutaneous route. It is not only effective, but also highly safe, with very few adverse reactions. The administration cycle is five months, which is much shorter than interferon. Take it for one year, and take life-necessary antiviral drugs.
The decline in the incidence of hepatitis B in Cuba shows that hepatitis B is not considered a health problem and that the Greater Antilles hopes to eliminate it completely by 2030, in line with the World Health Organization.